RDInvesting Provides Investors with Free In-Depth Equity Reports on BGS, DO, INTC and UTHR


Follow this company

Companies Mentioned

NYSE:BGS / NYSE:DO / NASDAQ:INTC / NASDAQ:UTHR
04/08/2014 [ACCESSWIRE]

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

B&G Foods, Inc. (NYSE: BGS) shares gained 6.02 percent to close at $33.47 a share Monday. The stock traded between $31.65 and $33.62 on volume of 792,100 shares traded. Analysts at RBC Capital Markets have recently upgraded the company’s rating to “outperform” from “sector perform”. Shares of B&G Foods have fallen approximately 1.0 percent year-to-date.

Find out more about B&G Foods including full access to the free equity report at:       
www.RDInvesting.com/BGS

Diamond Offshore Drilling Inc. (NYSE: DO) shares gained 0.85 percent to close at $48.79 a share Monday. The stock traded between $48.11 and $48.96 on volume of 2.50 million shares traded. Analysts at Standpoint Research have recently upgraded the company’s rating to "buy" from "hold". Shares of Diamond Offshore Drilling have fallen approximately 14.0 percent year-to-date.

Find out more about Diamond Offshore Drilling including full access to the free equity report at:     
www.RDInvesting.com/DO

Intel Corporation (NASDAQ: INTC) shares increased 1.24 percent to close at $26.49 a share Monday. The stock traded between $26.20 and $26.74 on volume of 49.66 million shares traded. Analysts at Pacific Crest have recently upgraded the company’s rating to "outperform" from "sector perform". Shares of Intel have gained approximately 2.0 percent year-to-date.

Find out more about Intel including full access to the free equity report at:        
www.RDInvesting.com/INTC

United Therapeutics Corporation (NASDAQ: UTHR) shares increased 2.65 percent to close at $93.35 a share Monday. The stock traded between $89.09 and $95.28 on volume of 1.40 million shares traded. Analysts at Standpoint Research have recently upgraded the company’s rating to "buy" from "hold". Shares of United Therapeutics have fallen approximately 17.0 percent year-to-date.

Find out more about United Therapeutics including full access to the free equity report at:       
www.RDInvesting.com/UTHR

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:            
Research Driven Investing      
info@rdinvesting.com

COMMENTS

Leave a comment...
 * 

Your Name
 *